Hormonal
Adjuvant pharmacotherapy with anti-obesity medications (AOMs) such as Liraglutide, Lorcaserin, or Naltrexone/Bupropion is effective and well-tolerated for managing weight regain or insufficient weight loss after bariatric surgery.
If you experience weight regain or insufficient weight loss after bariatric surgery, anti-obesity medications (like Liraglutide) can be a safe and effective option. Studies show they are well-tolerated and can help you lose additional weight, serving as a valuable tool for long-term management.
The largest study to date was a retrospective, multi-centre analysis of 317 patients using 15 different agents following SG or RYGB, where they found that 50% of patients were able to lose >5% of total weight... recent prospective study investigating the use of 3 mg liraglutide... found that in those completing >16 weeks of treatment, 23% lost >10% of their weight from baseline
Why this rating
Supported by retrospective studies and some prospective trials, but the paper notes limited RCTs and small sample sizes for post-surgical specific use.
Source
Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy
Alexis Sudlow et al. · Therapeutic Advances in Endocrinology and Metabolism · 2019
DOI 10.1177/2042018819875407
More from this paper
- Metabolic surgery provides superior short-term remission of type 2 diabetes and greater weight loss compared to pharmacotherapy alone, but long-term remission rates decline significantly over time.Good
- Long-term remission of Type 2 Diabetes following metabolic surgery is not sustained for the majority of patients, with remission rates dropping significantly after 5 years.Good
- A multimodal treatment approach combining metabolic surgery with adjuvant pharmacotherapy (specifically GLP-1 agonists or other anti-obesity drugs) is superior to surgery alone for maintaining long-term glycemic control and remission.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →